Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial

Luca Filippi*, Giacomo Cavallaro, Elettra Berti, Letizia Padrini, Gabriella Araimo, Giulia Regiroli, Valentina Bozzetti, Chiara De Angelis, Paolo Tagliabue, Barbara Tomasini, Giuseppe Buonocore, Massimo Agosti, Angela Bossi, Gaetano Chirico, Salvatore Aversa, Roberta Pasqualetti, Pina Fortunato, Silvia Osnaghi, Barbara Cavallotti, Maurizio VanniGiulia Borsari, Simone Donati, Giuseppe Nascimbeni, Giancarlo la Marca, Giulia Forni, Silvano Milani, Ivan Cortinovis, Paola Bagnoli, Massimo Dal Monte, Anna Maria Calvani, Alessandra Pugi, Eduardo Villamor, Gianpaolo Donzelli, Fabio Mosca

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number165
Number of pages10
JournalBmc Pediatrics
Volume17
DOIs
Publication statusPublished - 14 Jul 2017

Keywords

  • Propranolol
  • Beta blocker
  • Proliferative retinopathy
  • Angiogenesis
  • OXYGEN-INDUCED RETINOPATHY
  • ENDOTHELIAL GROWTH-FACTOR
  • BETA-ADRENERGIC-RECEPTOR
  • ORAL PROPRANOLOL
  • RETINAL NEOVASCULARIZATION
  • BETA-2-ADRENERGIC RECEPTOR
  • INFANTILE HEMANGIOMAS
  • BETA-3-ADRENERGIC RECEPTORS
  • FUNCTIONAL INVOLVEMENT
  • VISUAL IMPAIRMENT

Cite this

Filippi, L., Cavallaro, G., Berti, E., Padrini, L., Araimo, G., Regiroli, G., Bozzetti, V., De Angelis, C., Tagliabue, P., Tomasini, B., Buonocore, G., Agosti, M., Bossi, A., Chirico, G., Aversa, S., Pasqualetti, R., Fortunato, P., Osnaghi, S., Cavallotti, B., ... Mosca, F. (2017). Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial. Bmc Pediatrics, 17, [165]. https://doi.org/10.1186/s12887-017-0923-8